FB825 Drug Market

"FB825 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about FB825 for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the FB825 for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the FB825 for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FB825 market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

 

FB825  Drug Summary

FB825 is a humanized monoclonal antibody that binds to the CεmX domain of membrane form IgE, leading to the death of IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC). The drug has both therapeutic as well as preventive effects in allergic diseases. In April 2020, LEO Pharma signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan) covering the development and commercialization of the novel AD drug candidate, FB825. Under the agreement, Oneness became responsible for executing the Phase IIa study for AD in adults in the US, and LEO Pharma assumed all the development responsibilities after the Phase IIa studies. In April 2020, the company filed a patent application for treating IgE-mediated allergic diseases, including allergic asthma, allergic rhinitis, AD, and others, bearing the application number US16/862,512.

 

Scope of the FB825 Drug Market Report

The report provides insights into:

• A comprehensive product overview including the FB825 description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.

• Elaborated details on FB825 regulatory milestones and other development activities have been provided in this report.

• The report also highlights the FB825 research and development activities in atopic dermatitis across the United States, Europe and Japan.

• The report also covers the patents information with expiry timeline around FB825.

• The report contains forecasted sales of for atopic dermatitis till 2032.

• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.

• The report also features the SWOT analysis with analyst views for FB825 in atopic dermatitis.

 

FB825 Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

FB825 Analytical Perspective by DelveInsight

• In-depth FB825 Market Assessment

This report provides a detailed market assessment of FB825 for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• FB825 Clinical Assessment

The report provides the clinical trials information of FB825 for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

 

FB825 Drug Market Report Highlights  

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   

• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FB825 dominance.

• Other emerging products for atopic dermatitis are expected to give tough market competition to FB825 and launch of late-stage emerging therapies in the near future will significantly impact the market. 

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FB825 in atopic dermatitis.

• Our in-depth analysis of the forecasted sales data of FB825 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FB825 in atopic dermatitis. 

 

1 Report Introduction 
2 FB825 Overview in Atopic Dermatitis 
2.1 Product Detail
2.2 Clinical Development 
2.2.1 Clinical studies 
2.2.2 Clinical trials information 
2.2.3 Safety and efficacy 
2.3 Other Developmental Activities 
2.4 Product Profile 
3 Competitive Landscape (Marketed Therapies) 
4 Competitive Landscape (Late-stage Emerging Therapies) 
5 FB825 Market Assessment 
5.1 Market Outlook of FB825 in Atopic Dermatitis
5.2 7MM Market Analysis 
5.2.1 Market size of FB825 in the 7MM for atopic dermatitis 
5.3 Country-wise Market Analysis 
5.3.1 Market size of FB825 in the United States for atopic dermatitis 
5.3.2 Market size of FB825 in Germany for atopic dermatitis 
5.3.3 Market size of FB825 in France for atopic dermatitis 
5.3.4 Market size of FB825 in Italy for atopic dermatitis 
5.3.5 Market size of FB825 in Spain for atopic dermatitis 
5.3.6 Market size of FB825 in the United Kingdom for atopic dermatitis 
5.3.7 Market size of FB825 in Japan for atopic dermatitis 
6 SWOT Analysis 
7 Analysts’ Views 
8 Appendix 
8.1 Bibliography 
8.2 Report Methodology 
9 DelveInsight Capabilities 
10 Disclaimer 
11 About DelveInsight 
12 Report Purchase OptionsKey Questions

• What is the product type, route of administration and mechanism of action of FB825?

• What is the clinical trial status of the study related to FB825 in atopic dermatitis and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FB825 development?

• What are the key designations that have been granted to FB825 for atopic dermatitis?

• What is the forecasted market scenario of FB825 for atopic dermatitis?

• What are the forecasted sales of FB825 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  

• What are the other emerging products available and how are these giving competition to FB825 for atopic dermatitis?

• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?